Pontifax Venture Capital
Venture capitalHerzeliya Β· Pre-SeedβGrowth Β· 6 people tracked
Investment thesis
Pontifax targets breakthrough innovation irrespective of therapeutic area or development stage. The firm establishes its own portfolio companies and partners with existing management teams to develop early-stage ventures into mature businesses. Pontifax maintains hands-on portfolio management, actively directing the strategic course of each company investment.
Source: firm website, verified Jul 21, 2026.
Team Β· 6 people
from the firm's websiteCo-founder and managing partner of Pontifax overseeing a portfolio of more than 65 companies globally. He has extensive board experience with multiple successful exits including companies sold to Gilead, Merck, and Lilly, and currently chairs several portfolio company boards.
Co-founder and CEO of Pontifax who serves as an active board member across multiple portfolio companies with focus on strategic planning. He spent 10 years in senior management roles at top Israeli financial institutions investing in and managing technology-driven startups, and holds degrees from Harvard University in Economics and Law.
Joined Pontifax in 2018 bringing over 16 years of venture debt fund management experience. Previously served as General Partner at Viola Credit overseeing more than 100 debt transactions in mid to late-stage technology companies, and holds accounting and MBA credentials.
Principal at Pontifax involved in identifying and evaluating investment opportunities with expertise in rare disease and gene therapy biotech. She holds a PhD in biochemistry from Ben Gurion University and completed a postdoctoral fellowship at Albert Einstein College of Medicine researching infectious disease mechanisms.
Joined Pontifax in 2007 with over 15 years of financial and operational experience at Israeli and multinational venture capital firms. Previously served as CFO of Neurone Ventures Fund investing across telecom, enterprise, and life sciences sectors, and holds accounting and CPA credentials.
Joined Pontifax in 2009 to identify and evaluate new investment opportunities. He holds a Master's degree in Biology from Tel Aviv University and serves as a director across multiple portfolio companies in the biotech sector.
What they invest in
from 6 of 69 portfolio companiesBiotech Γ6Medical Devices Γ3Digital Health Γ1
HQs:United StatesΓ2BelgiumΓ1SwitzerlandΓ1
Investments Β· showing 60 of 69
founders shown can be your intro pathAgomab Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors targeting fibro-inflammation, with a focus on treating fibrotic diseases including Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis.
BiotechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.
BiotechBasel, CH
Thaminda(Chief Business Officer)Laetitia Pouzol(Chief Scientific Officer)Jill Marie JeneTom Mathers
LB Pharma develops novel therapies for neuropsychiatric disorders, with a lead product candidate called LB-102, an oral small molecule benzamide antipsychotic targeting schizophrenia, bipolar depression, and other neuropsychiatric diseases.
BiotechDigital Health
Frequently asked questions
- What stage does Pontifax Venture Capital invest at?
- Pontifax Venture Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Pontifax Venture Capital focus on?
- Pontifax Venture Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is Pontifax Venture Capital located?
- Pontifax Venture Capital is headquartered in Herzeliya, IL.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
F Prime Capital is an investment firm composed of scientists, engineers, physicians, operators, and investors who provide real-world expertise to help portfolio companies accelerate their path to scalable growth.